Akums Drugs and Pharmaceuticals (AKUMS) Q4 20/21 earnings summary

Executive summary

• Consolidated total income rose 12.37% YoY to INR 27,437.85 Mn; EBITDA increased 28.23% to INR 2,584.99 Mn, while total comprehensive income reached INR 1,233.08 Mn.

• COVID-19 made FY2020-21 challenging; manufacturing and marketing divisions reported turnover of INR 2,507 crore and INR 815 crore, respectively.

Financial highlights

• Consolidated revenue from operations increased 12.78% YoY to INR 27,226.29 Mn; total revenue rose from INR 24,416.43 Mn to INR 27,437.85 Mn.

• Consolidated EBITDA rose from INR 2,015.97 Mn to INR 2,584.99 Mn; total comprehensive income increased from INR 436.67 Mn to INR 1,233.08 Mn.

• Standalone total income rose to INR 8,919.49 Mn from INR 8,024.29 Mn; EBITDA was INR 812.181 Mn versus INR 1,054.478 Mn.

• Standalone PAT was a loss of INR 14,542.81 lakh, including an exceptional charge of INR 24,949.52 lakh; prior-year PAT was INR 5,085.85 lakh.

Outlook and guidance

• FY2021-22 API operations were expected to become fully operational, supporting backward integration and third-party API sales.

• Strategy prioritizes continued CRAMS strength, stronger API and branded/generic marketing, expansion of institutional and retail sales, and capacity additions organically or inorganically.

• StayHappi operated more than 1,600 retail stores; the business outlined an ambition to expand to about 15,000 outlets.